Multi-institution Phase I/Ib Study of Ibrutinib With ABT-199 in Relapsed/Refractory Mantle Cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2017
At a glance
- Drugs Venetoclax (Primary) ; Ibrutinib
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- 24 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
- 24 Oct 2017 Status changed from suspended to recruiting.
- 16 Mar 2017 Status changed from recruiting to suspended.